• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAR
Click for more information
1.96% 26.0¢

PARADIGM BIOPHARMACEUTICALS LIMITED..

Market Cap $90.94M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Paradigm Biopharmaceuticals Limited is a late-stage drug development company. It is... Paradigm Biopharmaceuticals Limited is a late-stage drug development company. It is engaged in researching and developing therapeutic products for human use. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS clears cellular and tissue accumulation of GAGs. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses (MPS); treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
PAR
research reports and media
67 68 69
13:58 4.1K 1.8M
13:58 Last post  Mozzarc Comments Created with Sketch.  4.1K  Views Created with Sketch.  1.8M 
PAR
Where we at?
7 8 9
26/05/24 485 159K
26/05/24 Last post  oxxa23 Comments Created with Sketch.  485  Views Created with Sketch.  159K 
PAR
Ann: Change in substantial holding 		23/05/24 12 5.2K
TRENDING NEWS

Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market

Read More   right-arrow Created with Sketch.
NEWS
27 May 2024
23/05/24 Last post  bedger Comments Created with Sketch.  12  Views Created with Sketch.  5.2K 
PAR
Charlie and the once in a lifetime post! 		23/05/24 52 16K
23/05/24 Last post  Mozzarc Comments Created with Sketch.  52  Views Created with Sketch.  16K 
PAR
Ann: Application for quotation of securities - PAR 		22/05/24 14 4.0K
22/05/24 Last post  Friendsandco Comments Created with Sketch.  14  Views Created with Sketch.  4.0K 
PAR
Capital Raise 		22/05/24 30 10K
22/05/24 Last post  mdro Comments Created with Sketch.  30  Views Created with Sketch.  10K 
PAR
FDA approval timeline and follow up timeline 		22/05/24 6 1.8K
22/05/24 Last post  bobsee Comments Created with Sketch.  6  Views Created with Sketch.  1.8K 

See All Discussions arrow Created with Sketch.

Timeline

Change in substantial holding
22 May 08:24
 
Application for quotation of securities - PAR
20 May 16:03
 
Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 09:54
 
Notification of cessation of securities - PAR
26 Apr 16:46
 
Type D Response Submitted and Received by the US FDA
19 Apr 08:36
 
Notification of cessation of securities - PAR
05 Apr 19:49
 
View More arrow Created with Sketch.

Featured News

TLX Telix gets its foot in the FDA door bringing prostate cancer detection closer to neglected Americans
right-arrow Created with Sketch.
VMS Venture hits 1,839 TREO at Jupiter in WA with best intersection to date
right-arrow Created with Sketch.
ARU More, more, more: Arafura eyes another US$300M in funding for flagship
right-arrow Created with Sketch.
NEWS The Telstra twist - What the job cuts decision mean for investors?
right-arrow Created with Sketch.
DY6 DY6 Metals (ASX:DY6) shares soar as company flags historical rare earth hits
right-arrow Created with Sketch.
PLY PlaySide to take gamers back to Westeros with new PC title
right-arrow Created with Sketch.
(20min delay)
Last
26.0¢ 		Change
0.005(1.96%) 		Mkt cap ! $90.94M
Open High Low Value Volume
26.5¢ 26.5¢ 25.5¢ $68.79K 263.0K

Buyers (Bids)

No. Vol. Price($)
6 230141 26.0¢
 

Sellers (Offers)

Price($) Vol. No.
26.5¢ 73718 8
View Market Depth
Last trade - 14.52pm 27/05/2024 (20 minute delay) ?
Last
26.0¢ 		  Change
0.005 ( 0.58 %)
Open High Low Volume
26.0¢ 26.5¢ 26.0¢ 101886
Last updated 14.52pm 27/05/2024 ?
PAR (ASX) Chart

Top Stories

Elixir reports rise of 328% in contingent resources at QLD gas project

Elixir Energy Ltd has reported an upgrade of 328% in its contingent resources at Queensland's Grandis Gas Project.
Critical minerals bounty in Angola points to prospect extension for Tyranna Tyranna Resources Ltd has picked up high grades in lithium, tantalum and caesium based on drilling at its Muvero prospect in Angola.
Elsight's Halo shines on take off in the Land of the Rising Sun Elsight’s Halo (ASX:ELS) has been selected by ACSL, Japan’s largest drone manufacturer, as the Beyond Vision Line Of Sight (BVLOS) Communications platform for its drones.Elsight announced today that ACSL had chosen Halo, in conjunction with new Japanese regional pa...
Market Update: ASX turns green with real estate flowering The ASX200 is trading up around 0.7 per cent.Most sectors are in the green, real estate has gained the most so far, up nearly 1.6%. Staples follows, up 1.2%.The utilities and energy sectors are the only two to slip into the red.Company newsReal estate company, Lendlease (ASX:LLC) is up nearly 10%...
Historical prospects impress Solstice, with 25% copper and significant anomaly Solstice Minerals Ltd has picked up impressive base metal mineralisation from historical analysis and sampling at two new prospects in WA.

Featured News

PLY PlaySide to take gamers back to Westeros with new PC title
right-arrow Created with Sketch.
NEWS Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market
right-arrow Created with Sketch.
ARU More, more, more: Arafura eyes another US$300M in funding for flagship
right-arrow Created with Sketch.
YRL Yandal lines up prime gold targets at Ironstone Well-Barwidgee
right-arrow Created with Sketch.
TLX Telix gets its foot in the FDA door bringing prostate cancer detection closer to neglected Americans
right-arrow Created with Sketch.
NMT Neometals eyeing 80% stake in US-based precious metal waste recovery plant
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.